- Home
- EPRX vs TARA Comparison
EPRX vs TARA Comparison
Compare EPRX & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPRX
- TARA
- Stock Information
- Founded
- EPRX 2011
- TARA N/A
- Country
- EPRX Canada
- TARA United States
- Employees
- EPRX N/A
- TARA N/A
- Industry
- EPRX
- TARA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EPRX
- TARA Health Care
- Exchange
- EPRX NYSE
- TARA Nasdaq
- Market Cap
- EPRX 130.0M
- TARA 136.3M
- IPO Year
- EPRX N/A
- TARA N/A
- Fundamental
- Price
- EPRX $3.28
- TARA $4.01
- Analyst Decision
- EPRX Strong Buy
- TARA Strong Buy
- Analyst Count
- EPRX 1
- TARA 4
- Target Price
- EPRX $9.00
- TARA $22.67
- AVG Volume (30 Days)
- EPRX 11.9K
- TARA 223.1K
- Earning Date
- EPRX 05-07-2025
- TARA 03-05-2025
- Dividend Yield
- EPRX N/A
- TARA N/A
- EPS Growth
- EPRX N/A
- TARA N/A
- EPS
- EPRX N/A
- TARA N/A
- Revenue
- EPRX N/A
- TARA N/A
- Revenue This Year
- EPRX N/A
- TARA N/A
- Revenue Next Year
- EPRX N/A
- TARA N/A
- P/E Ratio
- EPRX N/A
- TARA N/A
- Revenue Growth
- EPRX N/A
- TARA N/A
- 52 Week Low
- EPRX $2.20
- TARA $1.60
- 52 Week High
- EPRX $4.48
- TARA $10.48
- Technical
- Relative Strength Index (RSI)
- EPRX N/A
- TARA 43.01
- Support Level
- EPRX N/A
- TARA $4.41
- Resistance Level
- EPRX N/A
- TARA $4.63
- Average True Range (ATR)
- EPRX 0.00
- TARA 0.27
- MACD
- EPRX 0.00
- TARA -0.02
- Stochastic Oscillator
- EPRX 0.00
- TARA 5.30
About EPRX EUPRAXIA PHARMACEUTICALS INC
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with significant unmet medical needs.
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops, and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).